{"id":"NCT00621842","sponsor":"University Hospitals Cleveland Medical Center","briefTitle":"Lamotrigine for Symptoms of Geriatric Bipolar Depression","officialTitle":"Open-label, Prospective Trial of Lamotrigine for Symptoms of Geriatric Bipolar Depression","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-01","primaryCompletion":"2010-03","completion":"2010-03","firstPosted":"2008-02-22","resultsPosted":"2011-10-25","lastUpdate":"2014-12-30"},"enrollment":57,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Bipolar Disorder","Depression, Bipolar"],"interventions":[{"type":"DRUG","name":"Lamotrigine regular tablet formulation","otherNames":["Lamictal"]},{"type":"DRUG","name":"Lamotrigine novel formulation","otherNames":["Lamictal"]}],"arms":[{"label":"Open-Label Lamotrigine Treatment","type":"EXPERIMENTAL"}],"summary":"This is a 12-week, open label trial of lamotrigine for older adults (age 60 and older) with type I or type II Bipolar depression. Non-demented older adults with Bipolar I or II depression, confirmed via the Structured Clinical Interview for the Diagnostic and Statistical Manual for Mental Disorders (DSM) - Patient edition (SCID-I/P) and meeting inclusion criteria for depressive symptom severity (score of 18 or greater on the Hamilton Depression Rating Scale/HAM-D-24) will receive add-on lamotrigine dosed to a target of 200 mg/day.","primaryOutcome":{"measure":"Assessment of Change in Depressive Symptoms From Baseline on the Montgomery Asberg Depression Rating Scale (MADRS)","timeFrame":"12 weeks","effectByArm":[{"arm":"Open-label Lamotrigine Treatment","deltaMin":-15.5,"sd":null}],"pValues":[{"comp":"OG000","p":"<.01"}]},"eligibility":{"minAge":"60 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":13},"locations":{"siteCount":5,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":57},"commonTop":["Fall","Weight gain","Weight Loss","Rash","Vomiting"]}}